Nicholas Jacobus on Muck Rack

Nicholas Jacobus

United States
As seen in: MJH Life Sciences, Pharmaceutical Executive, EIN News, JD Supra, Lexology, Citeline, Pharmaceutical Technology, LexBlog, Pharmaceutical Commerce, Applied Clinical Trials, BioPharm International
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nicholas

Contact Nicholas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Additive Manufacturing's Application in Pharma and Biotech

|
By Nicholas Jacobus, Brian Hilberdink, Mike Hollan Verified
| EIN News
Kyle Smith, president and COO of Aprecia, discusses how additive manufacturing allows for the rapid development and manufacturing of a variety of dosage forms. Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications in a variety of dosages while achieving reliably consistent results. A major benefit of the process is the speed in which its able to produce a prototype and then shift to broad manufacturing.
Open in Who Shared Issue with article?

Cencora-Kite Agreement Signals CGT Commercialization Shift

|
By Cameron Olig, Stephen Appezzato Verified, Nicholas Jacobus
| Pharmaceutical Commerce Verified
Cencora has announced an agreement with Kite to support US distribution of the company's two FDA-approved CAR T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).`As Kite expands its treatment center network, it will leverage Cencora’s distribution infrastructure and services to support efficient access and reduce administrative burdens across sites of care, ultimately helping bring CAR T-cell therapies closer to patients who need them.1 How Could the...
Open in Who Shared Issue with article?

Q&A: Why Pharma Needs to Rethink Its Path to the Patient

|
By Stephen Appezzato Verified, Nicholas Jacobus, Cameron Olig
| Pharmaceutical Commerce Verified
Market access has become one of the most operationally complex and financially consequential functions in pharmaceutical commercialization. Gross-to-net pressure (GTN), formulary restrictions, and continue to demand attention from commercial teams, and survey data suggest the industry is actively reconsidering how it approaches access models and distribution.
Open in Who Shared Issue with article?
See all 54 licensed articles (1,007 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified